What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?

• Kokudo Takashi

  Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.

• Kokudo Norihiro

  Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.

抄録

In the past decade, there has been remarkable progress in surgical treatment for hepatocellular carcinoma (HCC) based on evidence created by epoch-making prospective trials or national registry big data analysis. A head-to-head randomized controlled trial comparing liver resection and local ablation for small oligo HCCs (SURF trial) demonstrated comparable recurrence-free survival provided both modalities are feasible. Survival benefit of liver resection for HCC with vascular invasion was demonstrated by two propensity scored matched analyses based on Japanese national data. Furthermore, expanded HCC criteria for living donor liver transplantation were developed based on Japanese national data, and this "5-5-500 rule" was accepted by the social insurance system in Japan. The recent remarkable progress in promising new anti-HCC agents may open the door for effective neoadjuvant or adjuvant treatment in combination with surgery.

収録刊行物

• Global Health & Medicine

  Global Health & Medicine 2 (5), 265-268, 2020-10-31

  国立研究開発法人 国立国際医療研究センター

キーワード

• hepatocellular carcinoma
• liver resection
• vascular invasion
• living donor transplantation
• molecular targeted agents
• immune-check point inhibitors

詳細情報

• CRID: 1391693801406446208
• NII論文ID: 130007936747
• DOI: 10.35772/ghm.2020.01086
• ISSN: 24349194
• ISSN: 24349186
• Web Site: https://www.jstage.jst.go.jp/article/ghm/2/5/2_2020.01086/_pdf
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可